[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,666
  • Shares Outstanding, K 23,268
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -22,700 K
  • EBIT $ -23 M
  • EBITDA $ -22 M
  • 60-Month Beta -0.31
  • Price/Sales 16.53
  • Price/Cash Flow N/A
  • Price/Book 3.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.28
  • Most Recent Earnings $-0.22 on 03/17/26
  • Next Earnings Date 05/13/26 [AMC]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-0.23
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) +44.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8402 +0.60%
on 05/08/26
1.1800 -28.37%
on 04/10/26
-0.2848 (-25.20%)
since 04/08/26
3-Month
0.4750 +77.94%
on 03/06/26
1.2300 -31.28%
on 04/07/26
+0.3322 (+64.76%)
since 02/06/26
52-Week
0.4750 +77.94%
on 03/06/26
1.8000 -53.04%
on 07/21/25
-0.6448 (-43.28%)
since 05/08/25

Most Recent Stories

More News
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs,...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron Announces Closing of Private Placement of up to $30 Million

$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
A $30 Million Reason to Buy Penny Stock Longeveron Today

Longeveron shares rip higher as the biotech firm raises $30 million via a private placement. Here’s why it may not be too late to invest in LGVN stock yet.

LGVN : 0.8452 (-0.77%)
Longeveron Announces Private Placement of up to $30 Million

$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant...

LGVN : 0.8452 (-0.77%)
LGVNR : 0.0005 (-37.50%)

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 0.9172
2nd Resistance Point 0.9008
1st Resistance Point 0.8730
Last Price 0.8452
1st Support Level 0.8288
2nd Support Level 0.8124
3rd Support Level 0.7846

See More

52-Week High 1.8000
Fibonacci 61.8% 1.2938
Fibonacci 50% 1.1375
Fibonacci 38.2% 0.9811
Last Price 0.8452
52-Week Low 0.4750

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.